By Mike Ward – Clarivate –
Longevity — once dismissed as the domain of futurists and fringe scientists — has rapidly emerged as one of the most compelling frontiers in drug development. The transformation hasn’t happened overnight, but since 2024, a convergence of scientific breakthroughs, regulatory evolution, and unprecedented commercial interest has propelled aging biology from academic curiosity to boardroom strategy.
The numbers tell part of the story: longevity-focused startups attracted $8.5 billion in venture capital in 2024 alone, more than doubling from the previous year’s downturn. The broader longevity market is projected to grow from $5.3 trillion in 2023 to $8 trillion by 2030.
